Drugs / Favirab®
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT01622062 Comparator | Jun 2012 → Nov 2018 | rabies | Sanofi Pasteur, a Sanofi Company | Completed | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Favirab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01622062 ↗ |
| Modality | Protein / enzyme biologic | “purified equine rabies immunoglobulin (pERIG)” PMID 30890382 ↗ Mar 2019 |
| Route | Other | “infiltrated into and around wound(s)” NCT01622062 ↗ |